STAAR Surgical makes and sells the Implantable Collamer Lens (ICL), a small foldable lens surgically inserted into the eye to correct refractive vision errors including myopia, hyperopia, and astigmatism. ICLs account for essentially all of STAAR's revenue. STAAR markets its ICL family under the "EVO" brand, positioning it as a premium alternative to laser vision correction procedures like LASIK and SMILE. Unlike laser procedures, the ICL is implanted without removing the patient's natural lens, making the procedure reversible. STAAR sells its ICLs on a per-unit basis to surgeons, clinics, and hospitals, at an ASP of roughly $500–$600 per lens globally. Because ICL surgery is elective and cash-pay, demand is sensitive to consumer confidence and disposable income. STAAR manufactures its lenses from Collamer, a proprietary collagen copolymer material, at facilities in Monrovia, California and Nidau, Switzerland. Gross margins are high, reflecting the premium, proprietary nature of the product, though margins compress when production volumes decline. STAAR is a highly global business, generating roughly 91% of revenue outside the U.S. China has historically been the largest single market, though its revenue share declined sharply in FY25 due to macroeconomic weakness and elevated distributor inventory. Outside China, key markets include Japan, South Korea, India, the U.S., and Europe. STAAR's growth strategy focuses on expanding ICL adoption globally through surgeon training and education, new product launches like EVO Viva (targeting presbyopia), and building out newer markets including the U.S. and India.